An evaluation of pharmaceutical treatment of dyslipidaemia among patients without diagnosed atherosclerotic disease in Belgium

International Journal of Clinical Practice

Volumn 57, Issue 8, 2003, Pages 720-725

  Devroey, Dirk ^a   Betz, W ^a   Kartounian, J ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BELGIUM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DYSLIPIDEMIA; EVALUATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REIMBURSEMENT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0242407539     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
2. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
3. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
4. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502,
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease a meta analysis of randomised controlled trials. JAMA 1999; 282: 2340-2346.
7. Xhignesse M, Laplante P, Niyonsenga T et al. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register. Can J Cardiol 2000; 16: 879-885.
8. Xhignesse M, Laplante P, Grant AM et al. Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: are we doing enough? Can J Cardiol 1999; 15: 185-189.
9. Svilaas A, Thoresen M, Kristoffersen JE et al. How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. Scand J Prim Health Care 2000; 18: 232-236.
10. De Henauw S, He Bacquer D, de Smet P et al. Trends and regional differences in coronary risk factors in two areas in Belgium: final results from the MONICA Ghent-Charleroi Study. J Cardiovasc Risk 2000; 7: 347-357.
11. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs evidence from a national cross sectional survey. BMJ 2000; 321: 1322-1325.
12. EUROASPIRE II study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572.
13. Svilaas A, Ose L, Risberg K, Thoresen M. Treatment goals for blood lipids in high risk patients of atherosclerotic disease. Tidsskr Nor Laegeforen 2001; 121: 1059-1063.
14. Muls E, De Backer G, De Bacquer D et al. LIPI-WATCH, a Belgian/Luxemburg survery on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest 2000; 19: 219-229.
15. Muls E, De Backer G, Brohet C, Heller F. The efficacy of atvorvastatin in treating patients with hypetcholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. Acta Cardiol 2001; 56: 109-114.
16. Strandberg TE, Pitkanen A, Larjo P et al. Attitude changes of general practitioners towards lowering LDL cholesterol. J Cardiovasc Risk 1998; 5: 43-46.
17. Henley E, Chang L, Hollander S. Treatment of hyperlipidemia. J Fam Pract 2002; 51: 370-376.
18. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204.
19. Danias PG, O'Mahony S, Radford MJ et al. Serum cholesterol levels are underevaluated and undertreated. Am J Cardiol 1998; 81: 1353-1356.
20. Harnick DJ, Cohen JL, Schechter CB et al. Effects of practice setting on quality of lipid-lowering management in patients With Coronary artery disease. Am J Cardiol 1998; 81: 1416-1420,
21. Shepherd J. A call to action. Eur Heart J 1998; 19: S2-7.
22. Wood D. Guidelines: a missed opportunity. Atherosclerosis 1999; 143: S7-S12.
23. Shepherd J. From best evidence to best practice: what are the obstacles? Atherosclerosis 1999; 147: S45-S51.